Back to search results

Soft Tissue Sarcoma

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

JGDR | {{ defaultRegistry.registryAnchorText }} NCT03283696 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety of ifosfamide when added to olaratumab and doxorubicin in participants with soft tissue sarcoma (STS) that is advanced or has spread to another part(s) of the body.

Completed Study

The results of this study are not yet available.

Time Commitment

Your participation could last up to 16 weeks, depending on how you and your tumor respond

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study


Male Female


18+ years
  • Participant must have been diagnosed with advanced soft tissue sarcoma

  • Participant must have adequate blood and organ function

  • Participant must have stopped other anti-cancer treatment and must have recovered from side effects of that treatment, except for hair loss

  • Female and male participant who is able to have children must agree to use birth control during the study and for 12 weeks after the last dose of study drug. Female participant must not be pregnant or breastfeeding

  • Participant must not be enrolled in another clinical trial

  • Participant must not have received anticancer treatment that targets the entire body (like chemotherapy) or radiotherapy of the chest or pelvis

  • Participant's cancer must not be actively spreading to the central nervous system or brain

  • Participant must not have active infections, including HIV or hepatitis

  • Participant must not have a mental illness or social situation that would make it hard to meet the study requirements

  • Participant must not be planning/need major surgery during the study

Where This Study Took Place Tool Tip Icon

Where This Study Took Place Tool Tip Icon

Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.